Note: This document contains side effect information about cyclobenzaprine. Some dosage forms listed on this page may not apply to the brand name Amrix.
Applies to cyclobenzaprine: oral extended-release capsules, oral immediate-release tablets.
Side effects include:
Drowsiness, dry mouth, dizziness, fatigue, headache.
For Healthcare Professionals
Applies to cyclobenzaprine: compounding powder, oral capsule extended release, oral tablet, oral and topical kit.
General
The most frequently occurring adverse reactions have included dry mouth, dizziness, fatigue, constipation, nausea, dyspepsia, and somnolence.[Ref]
Nervous system
Elderly patients may be particularly susceptible to the sedation and confusion which may accompany cyclobenzaprine (the active ingredient contained in Amrix) therapy.[Ref]
Very common (10% or more): Drowsiness (up to 38%)
Common (1% to 10%): Dizziness, somnolence
Postmarketing reports: Headache, serotonin syndrome, seizures, ataxia, tremors, hypertonia, convulsions, abnormal sensations, paresthesia, ageusia[Ref]
Psychiatric
Common (1% to 10%): Irritability, mental acuity decreased, nervousness
Postmarketing reports: Nervousness, confusion, disorientation, insomnia, depressed mood, anxiety, agitation, psychosis, abnormal thinking and dreaming, hallucinations, excitement[Ref]
Hypersensitivity
Postmarketing reports: Anaphylaxis, angioedema, pruritus, facial edema, urticaria, rash[Ref]
Gastrointestinal
Very common (10% or more): Dry mouth (up to 32%)
Common (1% to 10%): Constipation, nausea, dyspepsia, abdominal pain, acid regurgitation, diarrhea
Postmarketing reports: Unpleasant taste, vomiting, anorexia, gastritis, thirst, flatulence, tongue edema[Ref]
Hepatic
Postmarketing reports: Abnormal liver function, hepatitis, jaundice, cholestasis[Ref]
Cardiovascular
Postmarketing reports: Syncope, tachycardia, arrhythmia, vasodilation, palpitation, hypotension[Ref]
Other
Common (1% to 10%): Fatigue
Postmarketing reports: Asthenia, malaise, vertigo[Ref]
Dermatologic
Postmarketing reports: Sweating[Ref]
Genitourinary
Postmarketing reports: Urinary frequency and/or retention[Ref]
Musculoskeletal
Postmarketing reports: Local weakness, dysarthria, muscle twitching[Ref]
Ocular
Postmarketing reports: Blurred vision, diplopia, tinnitus[Ref]
Respiratory
Common (1% to 10%): Upper respiratory infection, pharyngitis[Ref]